BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shui L, Yang X, Li J, Yi C, Sun Q, Zhu H. Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy.Front Immunol. 2019;10:2989. [PMID: 32010123 DOI: 10.3389/fimmu.2019.02989] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 13.5] [Reference Citation Analysis]
Number Citing Articles
1 Velikova T, Krastev B, Lozenov S, Gencheva R, Peshevska-Sekulovska M, Nikolaev G, Peruhova M. Antibiotic-Related Changes in Microbiome: The Hidden Villain behind Colorectal Carcinoma Immunotherapy Failure. Int J Mol Sci 2021;22:1754. [PMID: 33578709 DOI: 10.3390/ijms22041754] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Cao Y, Jiang C, Jia Y, Xu D, Yu Y. Letrozole and the Traditional Chinese Medicine, Shaofu Zhuyu Decoction, Reduce Endometriotic Disease Progression in Rats: A Potential Role for Gut Microbiota. Evid Based Complement Alternat Med 2020;2020:3687498. [PMID: 32765629 DOI: 10.1155/2020/3687498] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Naqash AR, Kihn-Alarcón AJ, Stavraka C, Kerrigan K, Maleki Vareki S, Pinato DJ, Puri S. The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer. Ann Transl Med 2021;9:1034. [PMID: 34277834 DOI: 10.21037/atm-20-6427] [Reference Citation Analysis]
4 Kim J, Lee HK. The Role of Gut Microbiota in Modulating Tumor Growth and Anticancer Agent Efficacy. Mol Cells 2021;44:356-62. [PMID: 33972463 DOI: 10.14348/molcells.2021.0032] [Reference Citation Analysis]
5 Oliva M, Mulet-Margalef N, Ochoa-De-Olza M, Napoli S, Mas J, Laquente B, Alemany L, Duell EJ, Nuciforo P, Moreno V. Tumor-Associated Microbiome: Where Do We Stand? Int J Mol Sci 2021;22:1446. [PMID: 33535583 DOI: 10.3390/ijms22031446] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Milewska S, Niemirowicz-Laskowska K, Siemiaszko G, Nowicki P, Wilczewska AZ, Car H. Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment. Int J Nanomedicine 2021;16:6593-644. [PMID: 34611400 DOI: 10.2147/IJN.S323831] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Low L, Suleiman K, Shamdas M, Bassilious K, Poonit N, Rossiter AE, Acharjee A, Loman N, Murray PI, Wallace GR, Rauz S. Gut Dysbiosis in Ocular Mucous Membrane Pemphigoid. Front Cell Infect Microbiol 2022;12:780354. [DOI: 10.3389/fcimb.2022.780354] [Reference Citation Analysis]
8 Vitorino M, Baptista de Almeida S, Alpuim Costa D, Faria A, Calhau C, Azambuja Braga S. Human Microbiota and Immunotherapy in Breast Cancer - A Review of Recent Developments. Front Oncol 2022;11:815772. [DOI: 10.3389/fonc.2021.815772] [Reference Citation Analysis]
9 Cong X, Tian H, Liu S, Mao K, Chen H, Xin Y, Liu F, Wang X, Meng X, Zhu G, Wang J, Gao X, Tan H, Yang Y, Sun T. Cationic Liposome/DNA Complexes Mediate Antitumor Immunotherapy by Promoting Immunogenic Tumor Cell Death and Dendritic Cell Activation. ACS Appl Mater Interfaces 2020;12:28047-56. [DOI: 10.1021/acsami.0c08112] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
10 Vitale MG, Barbato C, Crispo A, Habetswallner F, Martino BM, Riccardi F, Maione A, Eisenwagen S, Vitale G, Cartenì G. ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-zeolite to prevent Chemotherapy-Induced Side Effects, in particular, Peripheral Neuropathy. Molecules 2020;25:E2297. [PMID: 32414185 DOI: 10.3390/molecules25102297] [Reference Citation Analysis]
11 Mehmood S, Faheem M, Ismail H, Farhat SM, Ali M, Younis S, Asghar MN. ‘Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics’. Front Mol Biosci 2022;9:783494. [DOI: 10.3389/fmolb.2022.783494] [Reference Citation Analysis]
12 Mori G, Pasca MR. Gut Microbial Signatures in Sporadic and Hereditary Colorectal Cancer. Int J Mol Sci 2021;22:1312. [PMID: 33525662 DOI: 10.3390/ijms22031312] [Reference Citation Analysis]
13 Li Y, Dong B, Wu W, Wang J, Jin H, Chen K, Huang K, Huang S, Yao Y. Metagenomic Analyses Reveal Distinct Gut Microbiota Signature for Predicting the Neoadjuvant Chemotherapy Responsiveness in Breast Cancer Patients. Front Oncol 2022;12:865121. [DOI: 10.3389/fonc.2022.865121] [Reference Citation Analysis]
14 Choudhry H. The Microbiome and Its Implications in Cancer Immunotherapy. Molecules 2021;26:E206. [PMID: 33401586 DOI: 10.3390/molecules26010206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Bouferraa Y, Chedid A, Amhaz G, El Lakkiss A, Mukherji D, Temraz S, Shamseddine A. The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges. Int J Mol Sci 2021;22:8036. [PMID: 34360802 DOI: 10.3390/ijms22158036] [Reference Citation Analysis]
16 Vivarelli S, Falzone L, Leonardi GC, Salmeri M, Libra M. Novel insights on gut microbiota manipulation and immune checkpoint inhibition in cancer (Review). Int J Oncol 2021;59:75. [PMID: 34396439 DOI: 10.3892/ijo.2021.5255] [Reference Citation Analysis]
17 Pandey PN, Saini N, Sapre N, Kulkarni DA, Tiwari DAK. Prioritising breast cancer theranostics: A current medical longing in oncology. Cancer Treat Res Commun 2021;29:100465. [PMID: 34598060 DOI: 10.1016/j.ctarc.2021.100465] [Reference Citation Analysis]
18 Liu P, Zhao G, Zhang L, Gong Y, Gu Y. Atractylenolide I inhibits antibiotic-induced dysbiosis of the intestinal microbiome. Ann Transl Med 2021;9:1539. [PMID: 34790745 DOI: 10.21037/atm-21-4656] [Reference Citation Analysis]
19 Yang M, Wang Y, Yuan M, Tao M, Kong C, Li H, Tong J, Zhu H, Yan X. Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: An up-to-date systematic review and meta-analysis. Int Immunopharmacol 2020;88:106876. [PMID: 32799113 DOI: 10.1016/j.intimp.2020.106876] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Long LL, Svenson KL, Mourino AJ, Michaud M, Fahey JR, Waterman L, Vandegrift KL, Adams MD. Shared and distinctive features of the gut microbiome of C57BL/6 mice from different vendors and production sites, and in response to a new vivarium. Lab Anim (NY) 2021;50:185-95. [PMID: 34127866 DOI: 10.1038/s41684-021-00777-0] [Reference Citation Analysis]
21 Roviello G, Iannone LF, Bersanelli M, Mini E, Catalano M. The gut microbiome and efficacy of cancer immunotherapy. Pharmacol Ther 2021;:107973. [PMID: 34453999 DOI: 10.1016/j.pharmthera.2021.107973] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Yuen RCF, Tsao SY. Embracing cancer immunotherapy with vital micronutrients. World J Clin Oncol 2021; 12(9): 712-724 [PMID: 34631438 DOI: 10.5306/wjco.v12.i9.712] [Reference Citation Analysis]
23 Olvera-Rosales LB, Cruz-Guerrero AE, Ramírez-Moreno E, Quintero-Lira A, Contreras-López E, Jaimez-Ordaz J, Castañeda-Ovando A, Añorve-Morga J, Calderón-Ramos ZG, Arias-Rico J, González-Olivares LG. Impact of the Gut Microbiota Balance on the Health-Disease Relationship: The Importance of Consuming Probiotics and Prebiotics. Foods 2021;10:1261. [PMID: 34199351 DOI: 10.3390/foods10061261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Kubeček O, Paterová P, Novosadová M. Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors. Life (Basel) 2021;11:1387. [PMID: 34947918 DOI: 10.3390/life11121387] [Reference Citation Analysis]
25 Rezasoltani S, Yadegar A, Asadzadeh Aghdaei H, Reza Zali M. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors. Cancer Med 2021;10:1141-54. [PMID: 33369247 DOI: 10.1002/cam4.3694] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Zou R, Wang Y, Ye F, Zhang X, Wang M, Cui S. Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome. Clin Transl Oncol 2021. [PMID: 34002348 DOI: 10.1007/s12094-021-02637-2] [Reference Citation Analysis]
27 Gopalakrishnan V, Weiner B, Ford C, Sellman B, Hammond S, Freeman D, Dennis P, Soria J, Wortman J, Henn M. Intervention strategies for microbial therapeutics in cancer immunotherapy. Immuno-Oncology Technology 2020;6:9-17. [DOI: 10.1016/j.iotech.2020.05.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
28 Husseini ZE, Haibe Y, Bouferraa Y, Kreidieh M, Darazi MA, Mukherji D, Temraz S, Charafeddine M, Shamseddine A. Total neoadjuvant therapy in patients with locally advanced rectal cancer: A tertiary medical center experience. Mol Clin Oncol 2021;15:220. [PMID: 34476104 DOI: 10.3892/mco.2021.2382] [Reference Citation Analysis]
29 Geum MJ, Kim C, Kang JE, Choi JH, Kim JS, Son ES, Lim SM, Rhie SJ. Broad-Spectrum Antibiotic Regimen Affects Survival in Patients Receiving Nivolumab for Non-Small Cell Lung Cancer. Pharmaceuticals (Basel) 2021;14:445. [PMID: 34066877 DOI: 10.3390/ph14050445] [Reference Citation Analysis]
30 Belluomini L, Caldart A, Avancini A, Dodi A, Trestini I, Kadrija D, Sposito M, Tregnago D, Casali M, Riva ST, Sartori G, Menis J, Milella M, Pilotto S. Infections and Immunotherapy in Lung Cancer: A Bad Relationship? Int J Mol Sci 2020;22:E42. [PMID: 33375194 DOI: 10.3390/ijms22010042] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Wang J, Yang HR, Wang DJ, Wang XX. Association between the gut microbiota and patient responses to cancer immune checkpoint inhibitors. Oncol Lett 2020;20:342. [PMID: 33123253 DOI: 10.3892/ol.2020.12205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
32 Wu Q, Liu J, Wu S, Xie X. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts. Int Immunopharmacol 2021;92:107303. [PMID: 33465728 DOI: 10.1016/j.intimp.2020.107303] [Reference Citation Analysis]
33 Vaziri F, Colquhoun S, Wan YY. Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome. Liver Res 2020;4:191-8. [PMID: 33343967 DOI: 10.1016/j.livres.2020.10.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
34 Halama N, Haberkorn U. The Unmet Needs of the Diagnosis, Staging, and Treatment of Gastrointestinal Tumors. Semin Nucl Med 2020;50:389-98. [PMID: 32768003 DOI: 10.1053/j.semnuclmed.2020.06.003] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Grenda A, Krawczyk P. Cancer trigger or remedy: two faces of the human microbiome. Appl Microbiol Biotechnol 2021;105:1395-405. [PMID: 33492450 DOI: 10.1007/s00253-021-11125-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
36 Leonardi GC, Candido S, Falzone L, Spandidos DA, Libra M. Cutaneous melanoma and the immunotherapy revolution (Review). Int J Oncol 2020;57:609-18. [PMID: 32582963 DOI: 10.3892/ijo.2020.5088] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
37 Szczyrek M, Bitkowska P, Chunowski P, Czuchryta P, Krawczyk P, Milanowski J. Diet, Microbiome, and Cancer Immunotherapy-A Comprehensive Review. Nutrients 2021;13:2217. [PMID: 34203292 DOI: 10.3390/nu13072217] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Wang Z, Wu X. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker. Cancer Med 2020;9:8086-121. [PMID: 32875727 DOI: 10.1002/cam4.3410] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
39 Nyein AF, Bari S, Hogue S, Zhao Y, Maller B, Sha S, Gomez MF, Rollison DE, Robinson LA. Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09210-2] [Reference Citation Analysis]
40 Halama N. Bowel inflammation in cancer patients: the microbiome, antibiotics and interleukin-9. Br J Cancer 2020;123:1469-70. [PMID: 32843683 DOI: 10.1038/s41416-020-01030-0] [Reference Citation Analysis]
41 Oh B, Boyle F, Pavlakis N, Clarke S, Eade T, Hruby G, Lamoury G, Carroll S, Morgia M, Kneebone A, Stevens M, Liu W, Corless B, Molloy M, Kong B, Libermann T, Rosenthal D, Back M. The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy? Cancers (Basel) 2021;13:4824. [PMID: 34638308 DOI: 10.3390/cancers13194824] [Reference Citation Analysis]